showed moderate protection against HIV acquisition. Here, for the first time, and in support 23 of the product licensure program, we report the impact of dapivirine packing polymorphism 24 on the in vitro performance of the 25 mg dapivirine ring product. Thermal, particle size, 25 powder x-ray diffraction and thermodynamic solubility analyses of dapivirine polymorphic 26 forms I and IV, both of which are persistent at room temperature and with form I being the 27 thermodynamically stable form, were conducted for micronized and non-micronized 
Particle size analysis

134
The particle size distributions (PSDs) of micronized and non-micronized forms of both 
Powder X-ray diffraction
144
Powder X-ray diffraction (PXRD) patterns of non-micronized and micronized DPV form
145
I and IV powders were obtained using a X'PERT Pro MPR X-ray diffractometer
146
(PANalytical Ltd., UK). Samples were pressed onto a zero background holder so that a smooth, flat surface was achieved and mounted in a rotating sample holder. In vitro release samples (25 µL) were injected onto a Thermo Scientific BDS Hypersil™
279
C18 HPLC column (150 mm x 4.6 mm, 3 µm particle size) fitted with a guard column. The
280
column was held at 45 °C and isocratic elution was performed using a mobile phase of 45%
281
HPLC-grade acetonitrile and 55% phosphate buffer (pH 3.0; 7.7 mM) with a run time of 8 282 min. DPV was detected at 240 nm after 6.1 min.
284
Statistical analyses
285
Where appropriate, data sets were analysed using a one-way ANOVA followed by post-
286
hoc analysis using the Tukey-Kramer multiple comparisons test. Analysis was conducted 287 using GraphPad Prism software and significance was noted for a P value of less than 0.05: 288 * = significant (0.01 < P < 0.05), ** = very significant (0.001 < P < 0.01), *** = extremely 289 significant (P < 0.001), ns = not significant (P > 0.05).
291
The similarity factor (f 2 ) -a logarithmic reciprocal square root transformation of one plus form I and form IV are presented in Figure 2A and 2B, respectively. showed a glass transition (T g ) with amorphous relaxation close to 80 °C, followed by an 318 exothermic recrystallization transition at 163 °C and the form II melt endotherm at 220 °C.
Results and Discussion
319
Similar thermal behaviour was observed for micronized DPV form I (DSC trace not shown, 320 but data presented in Table 1 ).
321
By comparison, the non-micronized DPV form IV showed two sharp melting endotherm for the non-micronized form IV material (DSC trace not shown, but data presented in Table   327 1), attributed to the smaller particle size of the micronized material and/or changes in 328 crystallinity induced during the micronization process. which require test specimens to have a flat surface and be at least 6 mm (1/4 in) thick. 
407
In clinical use, however, vaginal ring devices are not likely to undergo extensive tensile 408 deformation. Therefore, the test is primarily used as a quality performance measure for 409 comparison of different ring formulations and manufacturing processes.
In vitro release
412
Mean daily and cumulative release versus time plots for both DPV forms I and IV from 413 matrix-type vaginal rings into IPA+H 2 O and SVF+Tween media are presented in Figure 7 .
414
The declining daily release values with time ( Figures 7A and 7B) initial ring content values to assess mass balance. The data presented in Table 6 465 demonstrate almost identical cumulative release between the two polymorphs of 13.1 mg wherein molecular diffusion of drug through the silicone matrix is rate controlling. 51 The 493 data also clearly illustrate that neither DPV particle size nor the polymorphic form of DPV
494
influence the thermodynamic solubility value, irrespective of the release medium tested.
495
PXRD analysis of the residual DPV material after preparation of saturated solutions 496 confirmed the no form conversion was observed during the solubility analysis and 497 indicating that the results reflect the true solubility of each form (Table 8) . 
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